Video

Taletrectinib shows efficacy and tolerability in advanced ROS1+ NSCLC previously treated with entrectinib

Giredestrant plus everolimus new option in ER+, HER2– advanced breast cancer, post-CDK4/6 inhibitors

Circulating tumour DNA a useful marker in CRC treatment efficacy, but only alongside others

Enhancing breast cancer care through AI and collaboration

NSCLC brain metastases: TTFields after SRS delays intracranial progression without affecting QoL

Proton vs photon radiotherapy shows similar patient-reported quality of life in breast cancer patients

Apalutamide and salvage radiotherapy benefits luminal B subtype prostate cancer

ctDNA testing improves detection of treatable metastases compared to standard care in colorectal cancer

ADT with PORT is a good treatment option for men with unfavourable intermediate risk or favourable high risk PC